OTC · ADAPY

Adaptimmune Therapeutics PLC

Closing price No closing price on file for ADAPY from our free price source.

Latest quarter · ended Jun 30, 2025

Sales slipped and cash got weaker

descriptionFiled Aug 13, 2025
Revenue growthShrinking
−89.3%
Quarter ended Sep 30, 2023: +4.5% sales vs. a year beforeQuarter ended Dec 31, 2023: −97.9% sales vs. a year beforeQuarter ended Mar 31, 2024: −88.1% sales vs. a year beforeQuarter ended Jun 30, 2024: +2399.6% sales vs. a year beforeQuarter ended Sep 30, 2024: +458.8% sales vs. a year beforeQuarter ended Dec 31, 2024: +1294.8% sales vs. a year beforeQuarter ended Mar 31, 2025: +28.3% sales vs. a year beforeQuarter ended Jun 30, 2025: −89.3% sales vs. a year before
Sep '23Jun '25
$13.7M vs. $128M a year ago
Cash from operationsWorse
−$34.8M
Quarter ended Sep 30, 2023: −$45.2M cash from operationsQuarter ended Dec 31, 2023: −$14.7M cash from operationsQuarter ended Mar 31, 2024: −$31.9M cash from operationsQuarter ended Jun 30, 2024: $47.4M cash from operationsQuarter ended Sep 30, 2024: −$54.5M cash from operationsQuarter ended Dec 31, 2024: −$34.2M cash from operationsQuarter ended Mar 31, 2025: −$66.6M cash from operationsQuarter ended Jun 30, 2025: −$34.8M cash from operations
Sep '23Jun '25
−173% from $47.4M a year ago
Share countDiluting
+3.6%
Quarter ended Sep 30, 2023: 1362.73M sharesQuarter ended Dec 31, 2023: 1480.95M sharesQuarter ended Mar 31, 2024: 1533.37M sharesQuarter ended Jun 30, 2024: 1534.47M sharesQuarter ended Sep 30, 2024: 1535.3M sharesQuarter ended Dec 31, 2024: 1543.39M sharesQuarter ended Mar 31, 2025: 1590.31M sharesQuarter ended Jun 30, 2025: 1590.31M shares
Sep '23Jun '25
1590.31M shares vs. 1534.47M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Mixed Insiders: as of Nov 13 Funds: as of Mar 31, 2026
−1000+100 0
  • info
    No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

1 fund reports owning ADAPY

Holdings as of Mar 31, 2026

Insider trades · last 12 months

Real buys and sales

No insider filings loaded for the last 12 months.

Top holders

Biggest funds in ADAPY

As of Mar 31, 2026
FundOwnsValueChange
Rhumbline Advisers<0.1%$72

"Owns" is shares reported divided by shares outstanding.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast